Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Actinic keratosis
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Actinic keratosis

Warning

Focal areas of abnormal keratinocyte proliferation and differentiation induced by chronic exposure to ultraviolet radiation. Initially flat scaly papules, on sun-exposed sites, they may become significantly elevated from the skin surface, which may progress to frank carcinoma in situ or invasive squamous cell carcinoma. In patients with 10 or more AK there is a 10-15% risk of development of squamous cell carcinoma (SCC) at some stage. Prevalence is likely underestimated, as AK is difficult to measure reliably in individuals and populations. Limited UK studies showed 19-24% of individuals aged >60 had at least 1 AK. AKs were also present in 3-6% of men aged 40-49 years; linear increase in AKs shown between 60-80 years in men but not women; rate of AKs estimated at 149 per 1000 person-years.

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

Treatment/ therapy

Mild: flat, pink patch with slight scale or rough to touch  

  • Advise all patients on use of sun protection and emollients.

For lesion and field treatment for isolated or scattered AK with no suspicious features: 

  • Topical Fluorouracil 5% (Efudix) cream apply BD for 3-4 weeks.  
  • Actikerall (0.5% 5FU/10% salicylic acid solution) apply once daily for 6-12 weeks, useful for hyperkeratotic AKs. 
  • Imiquimod cream 5% applied 3 x weekly for 4 weeks or 3.75% cream applied od for 2 weeks repeated after 2 weeks. 
  • Diclofenac sodium (Solaraze) apply BD for 60-90 days. 

Counsel patient regarding side effects of chosen treatment 

 

Moderate: larger numbers of moderately thick keratotic red patches that are easily felt and seen 

  • Advise all patients on use of sun protection and emollients. 
  • Topical Fluorouracil 5% (Efudix) cream apply BD for 3-4 weeks.  
  • Imiquimod cream 5% applied 3 x weekly for 4 weeks or 3.75% cream applied od for 2 weeks repeated after 2 weeks. 
  • Actikerall (0.5% 5FU/10% salicylic acid solution) apply once daily for 6-12 weeks, useful for hyperkeratotic AKs 
  • Tirbanibulin (Klysiri) applied once daily for 5 consecutive days. 
  • Counsel patient regarding side effects of chosen treatment 
  • Cryotherapy for isolated hypertrophic lesions. 
  • Curettage or shave excision with histology sent for confirmation of diagnosis and to rule out early SCC. 
  • Surgical excision for individual keratoses that are symptomatic or have a thick hard surface scale. 
  • Photodynamic therapy [PDT] (refer to secondary care service) test

 

Severe: Any of the following high-risk factors: Thick AK with indurated base, growing rapidly, tender bleeding, ulcerating  

  • Advise all patients on use of sun protection and emollients. 
  • Rapid growth, an indurated base, ulceration (in the absence of topical therapy) could suggest SCC rather than AK. Topical treatment should only be commenced with specialist advice. 

Referral Management

Mild: flat, pink patch with slight scale or rough to touch  

Manage in primary care. Seek advice and guidance where there is diagnostic uncertainty.  

Many actinic keratosis can become tender/ulcerated during topical treatment but this should improve with topical steroid or cessation of treatment. Consider SCC if it does not. 

Suspect SCC if a lesion develops a thickened painful base or ulcerates. 

 

Moderate: larger numbers of moderately thick keratotic red patches that are easily felt and seen 

Seek advice and guidance if there is diagnostic uncertainty.  

Refer to secondary care if there is failure of response to one cycle of treatment (requires biopsy) or if multiple / relapsing AKs represent a management challenge. 

Many actinic keratoses can become tender/ulcerated during topical treatment but this should improve with topical steroid or cessation of treatment. Consider SCC if it does not. 

Suspect SCC if a lesion develops a thickened painful base or ulcerates. 

 

Severe: Any of the following high-risk factors: Thick AK with indurated base, growing rapidly, tender bleeding, ulcerating  

Tender, thickened, ulcerated or enlarging actinic keratoses, may be suspected SCC and should be referred on the USOC pathway. 

High risk patient factors: past history of skin cancer, extensive UV damage, immunosuppressed, very young, more than 10 AKs, high-risk site i.e. ear or lip. Advise a lower threshold for referral in this group. 

Clinical tips

  • Options for treatment of AKs in primary care are Efudix, Actikerall, Imiquimod and Solaraze. All treatments cause an inflammatory reaction; the efficacy is largely in proportion to the reaction. The reaction for Solaraze is less.  
  • If there is significant inflammation, you can reduce treatment e.g. to once daily, or pause treatment and consider a topical steroid e.g. Eumovate. 
  • Treatment for thicker lesions includes cryotherapy, curettage & cautery, surgical excision and PDT.  
  • Refer routinely for AKs if failure to respond to standard treatments.  
  • Refer urgently via USOC pathway for all tender, thickened, enlarging, bleeding or ulcerated AKs, particularly in high-risk sites. Studies suggest treatment of field change in high-risk patients may lessen risk of SCC. 
  • If high risk patient (past history of skin cancer, extensive UV damage, immunosuppressed, very young) consider referral to secondary care. 
  • Once a person develops actinic keratoses they have commenced a chronic disposition to UV-pathology and should consider sun protection and self-examination for potential skin cancers. Those with multiple AK and skin cancers may be candidates for nicotinamide prophylaxis. 

ICD search categories

Benign 

ICD11 code - EK90 

Editorial Information

Last reviewed: 01/04/2023

Next review date: 01/04/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society